title: Commentary: Evidence versus influence in the WHO procedure for approving essential medicines: misoprostol for maternal health.
authors: Global Health Policy and Innovation Unit, Queen Mary, University of London, London, UK colin.millard@qmul.ac.uk.
authors: Colin
authors: C
authors: Millard
authors: Global Health Policy and Innovation Unit, Queen Mary, University of London, London, UK.
authors: Allyson M
authors: AM
authors: Pollock
authors: Global Health Policy and Innovation Unit, Queen Mary, University of London, London, UK.
authors: Petra
authors: P
authors: Brhlikova
mesh_terms: D018954:Drugs, Essential; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000627:therapeutic use*; D010120:Oxytocics / Q000627:therapeutic use*; D011050:Policy Making; D006473:Postpartum Hemorrhage / Q000517:prevention & control; D011247:Pregnancy; D014944:World Health Organization
chemical_list: D018954:Drugs, Essential; D010120:Oxytocics; D016595:Misoprostol